PCRX - NASDAQ
Pacira BioSciences, Inc.
$22.48
+1.0%Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
At a Glance
Live SnapshotPacira BioSciences, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Minimal operating profit suggests high operating costs or pricing challenges. Scalability is concerning.
Net Profit Margin
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Effective Tax Rate
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Pacira BioSciences, Inc. Income Statement
PCRX • NASDAQ
| Pacira BioSciences, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||
726.4M | 701M | 675M | 666.8M | 541.5M | 429.6M | 421M | 337.3M | 286.6M | 276.4M | 249M | 197.7M | 85.6M | 39.1M | 15.7M | 14.6M | 15M | 13.9M | |
GROSS PROFIT | ||||||||||||||||||
(149.7M) | (170.4M) | (184.7M) | (199.3M) | (140.3M) | (117.3M) | (106.7M) | (86.8M) | (87.9M) | (110.1M) | (71.8M) | (77.4M) | (54.8M) | (32.1M) | (16.7M) | (12.3M) | (12.3M) | (17.5M) | |
576.7M | 530.5M | 490.3M | 467.5M | 401.3M | 312.3M | 314.3M | 250.4M | 198.7M | 166.3M | 177.2M | 120.2M | 30.8M | 6.9M | -1.1M | 2.3M | 2.7M | -3.5M | |
OPERATING INCOME | ||||||||||||||||||
(543.4M) | (603.9M) | (402.6M) | (407.5M) | (311.4M) | (266M) | (303.8M) | (233M) | (218.8M) | (198.3M) | (167.7M) | (125.4M) | (84.1M) | (56.2M) | (35M) | (24.7M) | (31.3M) | (41.8M) | |
(368.8M) | (294.1M) | (269.4M) | (254.5M) | (199.3M) | (193.5M) | (200.8M) | (177.3M) | (161.5M) | (152.6M) | (139M) | (106.7M) | (62.5M) | (46.3M) | (20.2M) | (6M) | (5M) | (8.6M) | |
(117.3M) | (81.6M) | (76.3M) | (84.8M) | (55.5M) | (59.4M) | (72.1M) | (55.7M) | (57.3M) | (45.7M) | (28.7M) | (18.7M) | (21.6M) | (9.9M) | (14.9M) | (18.6M) | (26.2M) | (33.2M) | |
33.3M | -73.4M | 87.7M | 60M | 89.9M | 46.4M | 10.5M | 15.9M | -24.9M | -32M | 9.5M | -5.2M | -53.3M | -49.3M | -39.1M | -22.4M | -28.5M | -45.4M | |
PRE-TAX INCOME | ||||||||||||||||||
(14.6M) | (16.6M) | (17.3M) | (35.6M) | (29M) | (25.7M) | (23.6M) | (21.9M) | (18M) | (7.1M) | (7.7M) | (8.3M) | (7.3M) | (1.8M) | (4.8M) | (4.9M) | (3.6M) | (3.5M) | |
8.1M | 3.1M | -5.9M | -31M | -28.1M | -21M | -16.3M | -15.5M | -14M | -5.7M | -7M | -7.9M | -7M | -1.5M | -4.5M | -3.8M | -3.5M | -3.3M | |
(57.3M) | (228.2M) | (56.9M) | (68.2M) | (56.5M) | (13M) | (30.9M) | -888K | (167K) | -82K | -165K | -159K | -47K | -111K | (0.0) | (0.0) | (0.0) | (0.0) | |
-16.4M | 10.3M | -26M | -46.7M | -33.5M | -26.3M | -21.2M | -16.3M | -17.5M | -5.8M | -7.3M | -8.4M | -11.1M | -3M | -4.2M | -4.8M | -3.2M | 3.5M | |
16.9M | -63.1M | 61.7M | 13.3M | 56.4M | 20.1M | -10.7M | -425K | -42.5M | -37.8M | 2.1M | -13.5M | -64.4M | -52.3M | -43.3M | -27.1M | -28.2M | -45.6M | |
NET INCOME | ||||||||||||||||||
(9.8M) | (36.5M) | (19.7M) | -2.6M | (14.4M) | -125.4M | (268K) | (46K) | (140K) | (105K) | (264K) | (173K) | -442K | (0.0) | (0.0) | (0.0) | (3.2M) | -3.5M | |
7M | -99.6M | 42M | 15.9M | 42M | 145.5M | -11M | -471K | -42.6M | -37.9M | 1.9M | -13.7M | -63.9M | -52.3M | -43.3M | -27.1M | -31.7M | -41.9M |
SEC Filings
PCRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 28, 2026 | January 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 05, 2025 | August 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 05, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your PCRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.